Navigation Links
AssureRx Health Raises $11 Million Series B Financing
Date:3/25/2011

CINCINNATI, March 25, 2011 /PRNewswire/ -- AssureRx Health, Inc. today announced the closing of an $11 million Series B financing. The personalized medicine company, which provides clinically-relevant information to help physicians select the right drug and the right dose for individual neuropsychiatric patients, will use the funds to expand direct sales and marketing for its first product, GeneSightRx®, and for second generation product development activities.

The financing was led by Claremont Creek Ventures and Sequoia Capital and included participation of existing investors Cincinnati Children's Hospital Medical Center, Mayo Clinic and CincyTech, as well as new investor Allos Ventures. John Steuart and Dr. Brad Webb of Claremont Creek Ventures have joined the AssureRx board of directors, increasing board membership to seven.

"Our goal is to build the leading medical informatics company providing pharmacogenetic and other treatment decision support products to help physicians individualize the treatment of patients with neuropsychiatric and other disorders,"  said James S. Burns, president and CEO of AssureRx.  "Claremont Creek and Sequoia bring to AssureRx a wealth of experience and capabilities in informatics, life science, internet marketing, and international business development. Their investment brings substantial strength to our medical informatics platform."

Steuart, managing director of Claremont Creek said, "Venture capital firms such as ours see the opportunity for disruptive change springing from new discoveries in human genetics.  AssureRx has enormous potential as an early leader in the transformation of neuropsychiatric treatment toward individualized patient treatment. GeneSightRx and future treatment decision support products hold the promise for faster, better patient outcomes and less costly care for psychiatric conditions such as clinical depression, anxiety disorder, and schizophrenia."

Warren Hogarth, partner at Sequoia Capital, said, "AssureRx products have the potential to provide significant assistance to physicians worldwide in selecting the appropriate medication for their patients. AssureRx is at the cutting edge of this trend as they address a very large existing market. We look forward to helping them build a world class company."

From a simple cheek swab, the GeneSightRx technology measures and analyzes clinically important genetic variants that determine how a patient's unique genetic make-up affects his or her ability to tolerate or effectively respond to psychotropic medications. Patient-specific genetic information obtained through GeneSightRx can assist physicians in the process of selecting appropriate antidepressant and antipsychotic medications for individual patients.

About Claremont Creek Ventures

Claremont Creek Ventures turbocharges the uncommon startup. As a seed and early stage venture firm, it embraces emerging technologies that accelerate company success, specifically in the healthcare/ IT, energy conservation, and security markets. Utilizing a proprietary life-cycle venturing program, it partners with East-Bay corridor–based entrepreneurs and institutions, including UC Berkeley, Lawrence Livermore Labs and UC Davis. Claremont Creek has more than $300 million in capital under management in two funds. CCV healthcare/IT investments include Gene Security Networks, Fluxion Biosciences, Tibion and Geneweave Biosciences.  For more information, visit www.claremontcreek.com.

About Sequoia Capital

Sequoia Capital provides venture capital funding to founders of startups who want to turn business ideas into enduring companies. As the "Entrepreneurs Behind the Entrepreneurs", Sequoia Capital's Partners have worked with innovators such as Steve Jobs of Apple Computer, Larry Ellison of Oracle, Bob Swanson of Linear Technology, Sandy Lerner and Len Bozack of Cisco Systems, Dan Warmenhoven of NetApp, Jerry Yang and David Filo of Yahoo!, Jen-Hsun Huang of NVIDIA, Michael Marks of Flextronics, Larry Page and Sergey Brin of Google, Chad Hurley and Steve Chen of YouTube, Dominic Orr and Keerti Melkote of Aruba Networks, Jonathan Kaplan of Pure Digital, Tony Hsieh of Zappos, Omar Hamoui of Admob and Steve Streit of Green Dot. To learn more about Sequoia Capital visit www.sequoiacap.com/us/healthcare.

About AssureRx Health

AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenetics and is dedicated to helping physicians determine the right drug at the right dose for individual patients suffering from neuropsychiatric and other disorders. The GeneSightRx analysis is based on pharmacogenetics, the study of the genetic factors that influence an individual's response to drug treatments, FDA approved manufacturers' drug labels, scientific and clinical peer-reviewed publications, and proven pharmacology. The company was founded in 2006 to commercialize industry-leading personalized medicine technology. Cincinnati Children's Hospital Medical Center and Mayo Clinic are equity holders and technology collaborators. To learn more about pharmacogenetics and GeneSightRx, please click here.

Contacts:
James S. Burns
President & CEO
AssureRx Health, Inc.
Tel: (513) 234-0510
e-mail: jburns@assurerxhealth.com

Andreas Marathovouniotis or David Schull
Russo Partners
Tel: (212) 845-4235 or (212) 845-4271
e-mail: andreas.marathis@russopartnersllc.com or david.schull@russopartnersllc.com


'/>"/>
SOURCE AssureRx Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AssureRx Appoints Senior Executives in Key Roles to Drive Company Growth
2. AssureRx Expands GeneSightRx® Pharmacogenetic Profile with Sixth Gene to Enhance Guidance of Psychiatric Drug Prescribing
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
5. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Tone Deafness Explained, from the Harvard Health Letter
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
10. ViroPharma to Present at Three Upcoming Healthcare Conferences
11. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... -- Research and Markets has announced the addition of ... Type, Application, Usability - Forecast to 2025" report to their ... , , ... to grow at a CAGR of around 3.2% from 2015 to ... include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research in ...
(Date:12/8/2016)...   TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... The West Virginia Medical Institute (WVMI) announced ... name change aligns the entire company with its existing Quality Insights branded projects ... are very proud of the achievements associated with the West Virginia Medical Institute ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , a New ... Conventional Data Capture Methods for Input to Electronic Health Records: A Comparative Usability ... the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... 2016 , ... With the increasing demand for dental implants, the National Association ... to inform dentists and patients about the safety issues related to dental restorations. According ... the U.S. is projected to reach $6.4 billion in 2018 with more than 30 ...
Breaking Medicine News(10 mins):